Alliqua’s listing on NASDAQ this week will increase the wound care provider’s visibility in the market, and ultimately increase its shareholder base, says the company’s CEO David Johnson. Shares of the micro-cap biotech have risen 25% so far in 2014 after the company transformed itself in 2013 with a reverse stock split, new management and a major investment from biotech giant Celgene to further its Biovance product line.
Subscribe to TheStreetTV on YouTube:
For more content from TheStreet visit:
Check out all our videos:
Follow TheStreet on Twitter:
Like TheStreet on Facebook:
Follow TheStreet on LinkedIn:
Follow TheStreet on Google+:
source
